FUKOKU MUTUAL LIFE INSURANCE Co continued to hold its stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,370 shares of the medical instruments supplier’s stock at the end of the second quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Becton, Dickinson and were worth $267,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and in the first quarter worth approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Becton, Dickinson and by 8.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 51 shares in the last quarter. Harfst & Associates Inc. boosted its position in Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares in the last quarter. Finally, Financial Architects Inc boosted its position in Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 54 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “FUKOKU MUTUAL LIFE INSURANCE Co Maintains Holdings in Becton, Dickinson and Company (BDX)” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/10/23/fukoku-mutual-life-insurance-co-maintains-holdings-in-becton-dickinson-and-company-bdx.html.

Several analysts have issued reports on the company. Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research raised Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $202.07.

Becton, Dickinson and Company (NYSE BDX) opened at 211.83 on Monday. The firm’s 50 day moving average price is $198.29 and its 200-day moving average price is $193.82. The stock has a market cap of $48.20 billion, a price-to-earnings ratio of 61.35 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $212.54.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the prior year, the company earned $2.35 earnings per share. The business’s revenue was down 5.1% compared to the same quarter last year. On average, equities analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were issued a dividend of $0.73 per share. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.38%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 over the last three months. 1.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.